Distributor inventory
Pioglitazone 15 mg (as pioglitazone hydrochloride)
Type 2 diabetes mellitus to improve blood sugar control, as monotherapy or in combination with other antidiabetic medicines (e.g., metformin, sulfonylureas, insulin) along with diet and exercise
Pioglitazone is a thiazolidinedione that activates PPAR-γ receptors, increasing insulin sensitivity in adipose tissue, muscle and liver. It reduces insulin resistance, decreases hepatic glucose production and improves peripheral glucose uptake.
Oral tablet. Take exactly as prescribed, usually once daily at the same time each day, with or without food. Continue diet and exercise; monitor blood glucose regularly. Do not stop or change dose without medical advice.
Common side effects of K-PIO 15MG may include:
Not for type 1 diabetes or diabetic ketoacidosis. Can cause or worsen heart failure—contraindicated in NYHA class III/IV; seek help for rapid weight gain, swelling or shortness of breath. Risk of fluid retention especially with insulin. Monitor liver function; avoid if active liver disease or significant ALT elevation. May increase risk of bone fractures (especially in women). Rare risk of macular edema—report vision changes. Use with caution in patients with history of bladder cancer or unexplained hematuria; assess risk/benefit. May cause ovulation in anovulatory women—use contraception if needed.
